KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Enterprise Value (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Enterprise Value for 7 consecutive years, with $2.6 billion as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 7.97% to $2.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 billion through Dec 2025, up 7.97% year-over-year, with the annual reading at $2.6 billion for FY2025, 7.97% up from the prior year.
  • Enterprise Value hit $2.6 billion in Q4 2025 for Royalty Pharma, up from $2.3 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of $4.2 billion in Q1 2021 to a low of $1.4 billion in Q2 2023.
  • Historically, Enterprise Value has averaged $2.5 billion across 5 years, with a median of $2.5 billion in 2023.
  • Biggest five-year swings in Enterprise Value: skyrocketed 4603.54% in 2021 and later crashed 44.83% in 2022.
  • Year by year, Enterprise Value stood at $2.9 billion in 2021, then fell by 23.73% to $2.2 billion in 2022, then skyrocketed by 40.15% to $3.1 billion in 2023, then dropped by 21.35% to $2.4 billion in 2024, then grew by 7.97% to $2.6 billion in 2025.
  • Business Quant data shows Enterprise Value for RPRX at $2.6 billion in Q4 2025, $2.3 billion in Q3 2025, and $2.5 billion in Q2 2025.